Nxera Pharma Secures Exclusive Lucerastat Rights in Japan and Asia-Pacific
Nxera Pharma secured exclusive rights to the Phase 3 oral Fabry disease therapy candidate lucerastat for Japan and selected Asia-Pacific markets.
Related stories
BLDR Reports Fiscal Q3 Profit Down 97.75%
BLDR reported fiscal third-quarter profit attributable to shareholders down 97.75% year over year, with basic EPS also reported.
M impact | EQUITY | Oct 30, 2026, 06:21 AM UTC
Global Dominion names new chairman and CEO
M impact | EQUITY | Oct 30, 2026, 06:20 AM UTC
AEDAS Homes Proposes Delisting Shares From Spanish Exchanges
M impact | EQUITY | Oct 30, 2026, 06:19 AM UTC
HSBC raises GE Vernova to Buy from Hold
M impact | EQUITY | Oct 30, 2026, 06:19 AM UTC
ResMed Publishes Q1 FY2027 Earnings Call Transcript
ResMed published a transcript of its Q1 fiscal 2027 earnings call.
M impact | EQUITY | Oct 30, 2026, 06:15 AM UTC
Microsoft Prices $25 Billion Senior Unsecured Notes Offering
Microsoft announced pricing for $25 billion in aggregate principal amount of senior unsecured notes.
H impact | EQUITY | Oct 30, 2026, 06:12 AM UTC